Literature DB >> 11111816

Rheopheresis: rheologic, functional, and structural aspects.

R Klingel1, C Fassbender, T Fassbender, B Erdtracht, J Berrouschot.   

Abstract

Rheopheresis is a specific application of membrane differential filtration, synonymous with double filtration plasmapheresis for extracorporeal hemorheotherapy, eliminating an exactly defined spectrum of high molecular weight proteins from human plasma (e.g.: fibrinogen, alpha-2-macroglobulin, low-density lipoprotein cholesterol, IgM). This results in the improvement of blood flow and microcirculation initiated by lowering blood and plasma viscosity, and erythrocyte aggregation. In this context, microcirculation stands not only for the patency of small blood vessels, but for the complete interactive network between plasma, blood cells, the vessel wall, and cellular and extracellular compartments of the surrounding tissue. Insufficient tissue oxygenation leads to tissue damage, e.g., a microcirculatory disorder develops, creating acute as well as chronic symptoms. Therefore, impaired microcirculation has a rheologic, functional, and structural dimension with respect to involved organs or tissues. Rheopheresis represents a specific therapeutic approach with an acute rheologic as well as chronic functional and structural effects, which was confirmed in pilot and controlled clinical studies for several organ systems. Data from 2 controlled clinical trials are available for the safe and effective treatment in patients with age-related macular degeneration.

Entities:  

Mesh:

Year:  2000        PMID: 11111816     DOI: 10.1046/j.1526-0968.2000.004005348.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  8 in total

1.  Inflammation-related erythrocyte aggregation in patients with inflammatory bowel disease.

Authors:  Liaz Zilberman; Ori Rogowski; Meirav Rozenblat; Itzhak Shapira; Jacob Serov; Pinhas Halpern; Iris Dotan; Nadir Arber; Shlomo Berliner
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

2.  Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART.

Authors:  Michael Janusz Koss; Peter Kurz; Theoharis Tsobanelis; Walter Lehmacher; Cordula Fassbender; Reinhard Klingel; Frank H J Koch
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-23       Impact factor: 3.117

3.  Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis.

Authors:  Jose S Pulido
Journal:  Trans Am Ophthalmol Soc       Date:  2002

4.  Sex differences in the expression of haemorheological determinants in individuals with atherothrombotic risk factors and in apparently healthy people.

Authors:  D Zeltser; O Rogowski; S Berliner; T Mardi; D Justo; J Serov; M Rozenblat; D Avitzour; I Shapira
Journal:  Heart       Date:  2004-03       Impact factor: 5.994

Review 5.  LDL-apheresis: technical and clinical aspects.

Authors:  Rolf Bambauer; Carolin Bambauer; Boris Lehmann; Reinhard Latza; Ralf Schiel
Journal:  ScientificWorldJournal       Date:  2012-04-30

6.  Long-term outcomes of rheohaemapheresis in the treatment of dry form of age-related macular degeneration.

Authors:  Jan Studnička; Eva Rencová; Milan Bláha; Pavel Rozsíval; Miriam Lánská; Vladimír Bláha; Jan Němčanský; Hana Langrová
Journal:  J Ophthalmol       Date:  2013-12-18       Impact factor: 1.909

7.  Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss.

Authors:  Milan Kostal; Jakub Drsata; Milan Bláha; Miriam Lánská; Viktor Chrobok
Journal:  J Otolaryngol Head Neck Surg       Date:  2017-06-29

8.  Dynamics of blood count after rheohemapheresis in age-related macular degeneration: possible association with clinical changes.

Authors:  Milan Košťál; Milan Bláha; Eva Rencová; Miriam Lánská; Pavel Rozsíval; Vera Kratochvilová; Hana Langrová
Journal:  Biomed Res Int       Date:  2014-03-06       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.